| BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript |
BioLineRx Ltd. (NASDAQ:BLRX ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Phil Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants Joe Pantginis - HC Wainwright John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2025-03-31 14:52:17 |
Czytaj oryginał (ang.) |
| BioLineRx Reports 2024 Financial Results and Provides Corporate Update |
- Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases - - Executed license agreement with Ayrmid Pharma Ltd. for APHEXDA ® (motixafortide) with $10 million upfront payment, up to $87 million in commercial milestones, and high double-digit royalties on net sales - - Completed financings raising combined gross proceeds of $19 million and reduced operating expense run rate by 70%, extending the Company's cash runway through H2 2026 - - Management to host conference call today, March 31 st, at 8:30 am EDT - TEL AVIV, Israel , March 31, 2025 /PRNewswire/ -- BioLineRx Ltd. |
prnewswire.com |
2025-03-31 11:00:00 |
Czytaj oryginał (ang.) |
| BioLineRx to Report 2024 Annual Results on March 31, 2025 |
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , March 24, 2025 /PRNewswire/ -- BioLineRx Ltd. |
prnewswire.com |
2025-03-24 09:00:00 |
Czytaj oryginał (ang.) |
| BioLineRx Issues Letter to Shareholders |
- Company outlines strategic long-term vision and financial outlook - TEL AVIV, Israel , Jan. 21, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today issued the following letter to shareholders. |
prnewswire.com |
2025-01-21 09:00:00 |
Czytaj oryginał (ang.) |
| BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares |
TEL AVIV, Israel , Jan. 17, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, announced today that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares, issued by the Bank of New York Mellon as depositary, from 15 ordinary shares per ADS to 600 ordinary shares per ADS. |
prnewswire.com |
2025-01-17 09:00:00 |
Czytaj oryginał (ang.) |
| Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet |
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping more than 200 points on Monday. |
benzinga.com |
2025-01-06 16:01:37 |
Czytaj oryginał (ang.) |
| BioLineRx Announces $10 Million Registered Direct Offering |
TEL AVIV, Israel , Jan. 6, 2025 /PRNewswire/ -- BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements for the purchase of an aggregate of 50,000,000 of the Company's American Depositary Shares (ADSs) (or ADS equivalents) and accompanying warrants to purchase up to an aggregate of 50,000,000 ADSs, at a purchase price of $0.20 per ADS (or per ADS equivalent) and accompanying warrant in a registered direct offering. |
prnewswire.com |
2025-01-06 10:57:00 |
Czytaj oryginał (ang.) |
| BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript |
BioLineRx Ltd. (NASDAQ:BLRX ) Q3 2024 Earnings Conference Call November 25, 2024 8:30 AM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Mali Zeevi - CFO Conference Call Participants Joe Pantginis - HC Wainwright Justin Walsh - Jones Trading John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2024-11-25 12:58:08 |
Czytaj oryginał (ang.) |
| BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd. |
– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% – – BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC – – BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion – – Trans actions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases – – BioLineRx will provide further corporate updates on its Q3 results conference call, which is scheduled for November 25 at 8:30 am ET – TEL AVIV, Israel , Nov. 21, 2024 /PRNewswire/ -- BioLineRx Ltd. |
prnewswire.com |
2024-11-21 08:30:00 |
Czytaj oryginał (ang.) |
| BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 |
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd. |
prnewswire.com |
2024-11-20 09:19:00 |
Czytaj oryginał (ang.) |
| BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024 |
- Findings suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle - - Data from proof-of-concept study shows that motixafortide was safe and well tolerated - - Oral presentation at ASH 2024 on Saturday, December 7, 2024 in San Diego, California - TEL AVIV, Israel and WALTHAM, Mass. , Nov. 5, 2024 /PRNewswire/ -- BioLineRx Ltd. |
prnewswire.com |
2024-11-05 11:00:00 |
Czytaj oryginał (ang.) |
| BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection |
Patient survey currently underway in partnership with the HealthTree Foundation; data expected in Q1 2025 TEL AVIV, Israel and WALTHAM, Mass. , Sept. 17, 2024 /PRNewswire/ -- BioLineRx Ltd. |
prnewswire.com |
2024-09-17 17:01:00 |
Czytaj oryginał (ang.) |
| BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript |
BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2024 Earnings Conference Call August 15, 2024 8:30 AM ET Company Participants John Lacey - Head of IR and Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2024-08-15 19:03:06 |
Czytaj oryginał (ang.) |
| BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates |
- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal for quarter; on-track to reach goal of ~60% by end of Q4 - - Doubled the number of centers ordering APHEXDA during the second quarter - - Entered into clinical trial agreement with St. Jude Children's Research Hospital to evaluate motixafortide for hematopoietic stem cell mobilization for gene therapies in sickle cell disease - - Management to host conference call today, August 15, at 8:30 am EDT - TEL AVIV, Israel , Aug. 15, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the second quarter ended June 30, 2024, and provided recent corporate and portfolio updates. |
prnewswire.com |
2024-08-15 11:00:00 |
Czytaj oryginał (ang.) |
| BioLineRx to Report Second Quarter 2024 Results on August 15, 2024 |
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 8, 2024 /PRNewswire/ -- BioLineRx Ltd. |
prnewswire.com |
2024-08-08 11:00:00 |
Czytaj oryginał (ang.) |
| Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025 |
Making millions through the stock market is only possible in a few ways. Investors need one of these three things: Massive sums of capital to begin with Decades of time and more modest sums of capital More modest sums of capital and a combination of risk and luck We will be talking about the latter today: seven stocks you can buy for $2 that can 10X by 2025. |
investorplace.com |
2024-06-05 19:17:00 |
Czytaj oryginał (ang.) |
| BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) |
- Investigator-initiated study includes leading researchers in SCD gene therapy clinical development from St. Jude Children's Research Hospital, Inc. and two other clinical sites - - New trial to expand ongoing clinical research of motixafortide for mobilization of HSCs in patients with SCD - TEL AVIV, Israel , May 30, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a multi-center Phase 1 clinical trial sponsored by St. Jude Children's Research Hospital, Inc. to evaluate motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with sickle cell disease (SCD). |
prnewswire.com |
2024-05-30 11:00:00 |
Czytaj oryginał (ang.) |
| BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript |
BioLineRx Ltd. (NASDAQ:BLRX ) Q1 2024 Earnings Call Transcript May 28, 2024 8:30 AM ET Company Participants John Lacey - Head of IR and Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO Conference Call Participants Joe Pantginis - HC Wainwright John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2024-05-28 21:56:01 |
Czytaj oryginał (ang.) |
| BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates |
- Steady growth in APHEXDA ® adoption in first full quarter post-approval - - Among top 80 transplant centers, secured APHEXDA formulary placement to date at institutions representing ~26% of stem cell transplant procedures performed - on track to reach stated goal of ~35% by end of Q2 - - Announced new data in abstract accepted at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting on pilot phase of ongoing Phase 2b pancreatic cancer clinical trial collaboration with Columbia University - - Collaboration partner Gloria Biosciences' motixafortide HSC mobilization bridging study IND was filed and approved by the Center for Drug Evaluation of the National Medical Products Administration in China. Anticipate clinical trial initiation 2H 2024 - - Completed debt and equity financing totaling $26 million to support U.S. commercialization of APHEXDA and advance lifecycle expansion activities - - Management to host conference call today, May 28, at 8:30 am EDT - TEL AVIV, Israel , May 28, 2024 /PRNewswire/ -- BioLineRx Ltd. |
prnewswire.com |
2024-05-28 11:00:00 |
Czytaj oryginał (ang.) |
| BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting |
New analysis of biopsy samples demonstrated a significant increase in CD8+ T-cell density in tumors from all 11 patients treated 7 of 11 patients in the pilot phase experienced a partial response, with 6 confirmed; 10 of 11 patients experienced disease control Poster Presentation on Saturday, June 1, 2024 in Chicago, Illinois TEL AVIV, Israel , May 24, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that an abstract including new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial was accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois. |
prnewswire.com |
2024-05-24 11:00:00 |
Czytaj oryginał (ang.) |
| BioLineRx to Report First Quarter 2024 Results on May 28, 2024 |
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , May 22, 2024 /PRNewswire/ -- BioLineRx Ltd. |
prnewswire.com |
2024-05-22 11:00:00 |
Czytaj oryginał (ang.) |
| BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification |
TEL AVIV, Israel , May 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a notification letter from the Nasdaq Stock Market LLC ("Nasdaq"). |
prnewswire.com |
2024-05-17 21:00:00 |
Czytaj oryginał (ang.) |
| BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024 |
- Presentation Today, Monday, May 6, 2024 in Atlanta, Georgia - TEL AVIV, Israel , May 6, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that new economic model data will be presented on APHEXDA® (motixafortide) for CD34+ hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – The Professional Society for Health Economics and Outcomes Research – 2024 conference, taking place May 5-8, 2024, in Atlanta, Georgia. |
prnewswire.com |
2024-05-06 11:00:00 |
Czytaj oryginał (ang.) |
| BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting |
TEL AVIV, Israel , April 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a poster presentation on apheresis center efficiency and CXCR4 antagonists including APHEXDA (motixafortide) in patients with multiple myeloma. |
prnewswire.com |
2024-04-17 11:00:00 |
Czytaj oryginał (ang.) |
| BioLineRx Announces $6 Million Registered Direct Offering |
TEL AVIV, Israel , April 1, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 7,500,000 of the Company's American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 7,500,000 ADSs, at a combined purchase price of $0.80 per ADS and accompanying warrant. |
prnewswire.com |
2024-04-01 13:00:00 |
Czytaj oryginał (ang.) |
| BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates |
- Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on formulary approvals at targeted major transplant centers; r eceived Healthcare Common Procedure Coding System (HCPCS) J-Code to facilitate Medicare reimbursement - - Announced first patient dosed in randomized Phase 2b clinical trial evaluating motixafortide in first-line pancreatic cancer - - Continued to support partner Gloria Biosciences in plans to execute pivotal bridging study of motixafortide in stem cell mobilization and Phase 2b randomized study in first-line pancreatic cancer in China - - Management to host conference call today, March 26, at 8:30 am EDT - TEL AVIV, Israel , March 26, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its financial results for the year ended December 31, 2023, and provided recent corporate and portfolio updates. |
prnewswire.com |
2024-03-26 09:00:00 |
Czytaj oryginał (ang.) |
| BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) |
- Conducted in Collaboration with Columbia University, the CheMo4METPANC Phase 2 trial is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies compared to chemo alone - - Gulam Manji, MD, PhD, of Columbia University to present encore pilot phase data at the Immuno-Oncology (IO) 360° Summit on February 29 - TEL AVIV, Israel , Feb. 28, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that the first patient has been dosed in the randomized CheMo4METPANC Phase 2 combination clinical trial evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC). |
prnewswire.com |
2024-02-28 09:00:00 |
Czytaj oryginał (ang.) |